Sector News

China’s Abogen raises $700M series C for mRNA trials, catapulting itself into the big leagues

August 22, 2021
Life sciences

Abogen Biosciences has raised one of the largest private biotech funding rounds ever. The low-profile biotech reeled in more than $700 million to advance its late-phase COVID-19 jab, obliterating the fundraising record for a Chinese mRNA vaccine developer.

The COVID-19 crisis put Abogen on the map, with its $92 million series B round and initiation of the first phase 3 clinical trial of a Chinese mRNA vaccine making headlines earlier this year, but the size of its latest financing still came as a shock.

Stemirna Therapeutics’ $188 million financing raised the bar for Chinese mRNA rounds in June. Abogen has now launched the bar into rarefied air occupied by few other biotechs, from anywhere, working on any modality.

Temasek, Invesco Developing Markets Fund, Loyal Valley Capital, GL Ventures, Yunfeng Capital, Lilly Asia Ventures and Boyu Capital came together to lead the round, with about 20 new and existing investors providing assists.

Abogen will use the money to fund development of a COVID-19 vaccine that entered phase 3 in April. While Abogen has ceded a huge head start to mRNA vaccines from Moderna and Pfizer-BioNTech, its candidate may have an advantage over those products. Last year, Bo Ying, founder of Abogen, co-authored a paper about a thermostable mRNA vaccine against COVID-19.

The paper describes how Abogen’s lipid nanoparticle-encapsulated mRNA vaccine ARCoV remained stable at 25 degrees Celsius for at least seven days. Exposing the vaccine to temperatures of 37 degrees Celsius for seven days resulted in a 13% drop in relative photon flux. A vaccine that is stable at ambient temperatures for a week or more could help get supplies to rural areas that lack cold chain infrastructure.

Abogen still needs to show its vaccine works, though. The success of Moderna and Pfizer-BioNTech show mRNA vaccines can be highly effective, although the struggles of CureVac provide a cautionary tale.

The size of the round will enable Abogen to complete clinical development of ARCoV while adding to its production capabilities and moving more vaccines and oncology mRNA candidates into the clinic.

by Nick Paul Taylor

Source: fiercebiotech.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).